

Resource Summary Report

Generated by [kravitz2](#) on Sep 23, 2026

Common Terminology Criteria for Adverse Events

RRID:SCR_010296

Type: Tool

Proper Citation

Common Terminology Criteria for Adverse Events (RRID:SCR_010296)

Resource Information

URL: <http://purl.bioontology.org/ontology/CTCAE>

Proper Citation: Common Terminology Criteria for Adverse Events (RRID:SCR_010296)

Description: A coding system for reporting adverse events that occur in the course of cancer therapy. It was derived from the Common Toxicity Criteria (CTC) v2.0 and is maintained by the Cancer Therapy Evaluation Program (CTEP) at the National Cancer Institution (NCI).

Abbreviations: CTCAE

Resource Type: controlled vocabulary, data or information resource, ontology

Keywords: owl

Related Condition: Cancer

Resource Name: Common Terminology Criteria for Adverse Events

Resource ID: SCR_010296

Alternate IDs: nlx_157370

Record Creation Time: 20220129T080257+0000

Record Last Update: 20260919T195153+0000

Ratings and Alerts

No rating or validation information has been found for Common Terminology Criteria for Adverse Events.

No alerts have been found for Common Terminology Criteria for Adverse Events.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 14 mentions in open access literature.

Listed below are recent publications. The full list is available at [kravitz2](#) .

Ponz-Sarvis M, et al. (2026) Lenvatinib plus Pembrolizumab for Patients with Previously Treated Advanced Gastric, Biliary Tract, or Pancreatic Cancer: Results from the Phase II LEAP-005 Study. *Cancer research communications*, 6(3), 673.

Ahluwalia MS, et al. (2026) Efficacy and CNS Toxicity of Nivolumab and Ipilimumab in Rare Cancer Brain Metastases: A Multicenter Basket Trial Analysis (NCI/SWOG S1609). *Clinical cancer research : an official journal of the American Association for Cancer Research*, 32(10), 1928.

Guercio BJ, et al. (2026) Neoadjuvant Nivolumab with or without Ipilimumab for Cisplatin-Ineligible Patients with Muscle-Invasive Bladder Cancer. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 32(8), 1434.

Meng X, et al. (2026) Cancer Treatment-Related Cardiotoxicity among Survivors of Childhood Cancer: A Comparative and Integrated View of Multiple Measures of Biological Age Acceleration. *Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology*, 35(5), 718.

Siu LL, et al. (2025) A First-in-Human Study of ATM Inhibitor Lartisertib as Monotherapy in Patients with Advanced Solid Tumors. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 31(21), 4429.

Luke JJ, et al. (2025) Intratumoral or Subcutaneous MK-2118, a Noncyclic Dinucleotide STING Agonist, with or without Pembrolizumab, for Advanced or Metastatic Solid Tumors or Lymphomas. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 31(7), 1233.

Meric-Bernstam F, et al. (2025) Phase 2 Study of Zilovetamab Vedotin in Participants with Metastatic Solid Tumors. *Cancer research communications*, 5(9), 1664.

van Ravensteijn SG, et al. (2025) Cemiplimab in Locally Advanced or Metastatic Secondary Angiosarcomas (CEMangio): A Phase II Clinical Trial and Biomarker Analyses. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 31(17), 3678.

Harrington KJ, et al. (2025) Phase I and II Clinical Studies of the STING Agonist Ulevostinag with and without Pembrolizumab in Participants with Advanced or Metastatic Solid Tumors or Lymphomas. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 31(16), 3400.

Kawazoe A, et al. (2024) Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Gastric Cancer Cohort. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 30(7), 1264.

Nawrocki ST, et al. (2023) Comprehensive Single-Cell Immune Profiling Defines the Patient Multiple Myeloma Microenvironment Following Oncolytic Virus Therapy in a Phase Ib Trial. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 29(24), 5087.

Schwartz LF, et al. (2023) The Association of Neighborhood Characteristics and Frailty in Childhood Cancer Survivors: A Report from the St. Jude Lifetime Cohort Study. *Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology*, 32(8), 1021.

Lu YS, et al. (2022) Updated Overall Survival of Ribociclib plus Endocrine Therapy versus Endocrine Therapy Alone in Pre- and Perimenopausal Patients with HR+/HER2- Advanced Breast Cancer in MONALEESA-7: A Phase III Randomized Clinical Trial. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 28(5), 851.

Harat M, et al. (2022) Safety and Efficacy of Irradiation Boost Based on 18F-FET-PET in Patients with Newly Diagnosed Glioblastoma. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 28(14), 3011.